Reference : Le medicament du mois. Sitagliptine (Januvia): incretinopotentiateur indique comme in...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Le medicament du mois. Sitagliptine (Januvia): incretinopotentiateur indique comme insulinosecretagogue dans le traitement du diabete de type 2.
[en] Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Van Gaal, L. F. mailto [Hôpital universitaire d’Anvers. > Département de Diabétologie, Métabolisme et Nutrition clinique > > >]
Revue Médicale de Liège
Yes (verified by ORBi)
[en] Belgium ; Diabetes Mellitus, Type 2/drug therapy ; Glucagon-Like Peptide 1/drug effects/metabolism ; Humans ; Hypoglycemic Agents/adverse effects/pharmacokinetics/therapeutic use ; Incretins/metabolism ; Insulin/secretion ; Insurance, Health, Reimbursement ; Insurance, Pharmaceutical Services ; Pyrazines/adverse effects/pharmacokinetics/therapeutic use ; Triazoles/adverse effects/pharmacokinetics/therapeutic use
[en] Sitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1). This hormone is mainly secreted by ileal L cells and this secretion is abnormally low in patients with type 2 diabetes. Sitagliptin increases post-meal insulin secretion ("incretin effect) by enhancing the postprandial GLP-1 response ("incretin enhancer"), in a glucose-dependent manner. It improves glycaemic control (HbA1c) in type 2 diabetic patients treated by diet alone, by metformin, by sulfonylurea, by glitazone or by a metformin-sufonylurea combined therapy. The glucose-lowering effect is similar to that of glipizide, but with the advantage of no weight gain and no hypoglycaemic episodes. The tolerance to sitagliptin is excellent. Treatment is simple, with 100 mg once daily, without need of titration or home blood glucose monitoring. In Belgium, sitagliptin is currently reimbursed in patients with type 2 diabetes not adequately controlled with diet and metformin monotherapy.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
200802_11.pdfNo commentaryPublisher postprint494.71 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.